17.08.23.Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
(WorldNews Health)

ASX ANNOUNCEMENT 23 August 2017 Positive Data from Cynata MSCs in Second Preclinical Asthma Study Clear efficacy data for Cynata`s proprietary CymerusTM MSCs in second preclinical study in a clinically-relevant model of asthma Cymerus MSCs caused significantly greater reduction of airway hyperresponsiveness compared to corticosteroid treatment Data suggest Cymerus MSCs can be administered alone or in combination with corticosteroids to treat the airway hyperresponsiveness associated with asthma Completion of this study will further advance the path towards clinical trials Melbourne, Australia; 23 August 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited...